



## Antimicrobial Therapeutics for Bone and Periprosthetic Joint Infection

Guest Editors:

**Prof. Dr. Éric M. Senneville**

Service de Maladies Infectieuses  
et Tropicales, Centre Hospitalier  
de Tourcoing, 59200 Tourcoing,  
Nord-Pas-de-Calais, France

**Dr. Olivier Robineau**

Service de Maladies Infectieuses  
et Tropicales, Centre Hospitalier  
de Tourcoing, 59200 Tourcoing,  
Nord-Pas-de-Calais, France

Deadline for manuscript  
submissions:

**31 October 2024**

### Message from the Guest Editors

Dear Colleagues,

Osteomyelitis and periprosthetic joint infections (PJIs) have gained interest in the last decades. While the surgical part of the management of such infections is based on general rules generally well admitted, it is not the case for the antimicrobial part. Indeed, the numerous antimicrobial agents including new antibiotics result in a huge number of potential antimicrobial regimens. Recent studies have highlighted the potential role of bacteria in the recurrence of osteomyelitis which might result in another possible way to fight against this issue. Suppressive antimicrobial therapy is used by some teams but it still needs clarification in its definition and modalities of administration. The question of both duration and oral administration of antimicrobial therapy for osteomyelitis and PJIs has been addressed. This Special Issue seeks manuscript submissions that further our understanding of antimicrobial therapy for osteomyelitis and PJIs. Submissions on new antimicrobial approaches especially bacteriophages, prevention of recurrence, and innovative antimicrobial regimens are especially encouraged.

Prof. Dr. Éric M. Senneville  
Dr. Olivier Robineau





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1  
(*General Pharmacology, Toxicology and Pharmaceutics*)

## Contact Us

*Antibiotics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/antibiotics](http://mdpi.com/journal/antibiotics)  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)  
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)